CEL SCI CORP — Regulatory Filings 2017

Jun 6, 2017

8-K 1 cvm_8k.htm CURRENT REPORT Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2017 Issuer Direct Corporation Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 5, 2017

CEL-SCI CORPORATION

(Exact name of Registrant as specified in its charter)

Colorado	001-11889	84-0916344
(State
or other jurisdiction	(Commission File
No.)	(IRS
Employer
of
incorporation)		Identification
No.)

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (703) 506-9460

N/A

(Former name or former address if changed since last report)

page break

Item 8.01 Other Events

On June 5, 2017 the Company issued a press release, filed as Exhibit 99, announcing that it has responded to the U.S. Food and Drug Administration’s (FDA) most recent communication.

Item 9.01 Exhibits

Exhibit
Number	Description of
Document
99	June 5,
2017 Press Release.

page break

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date:
June 5, 2017 | |
| --- | --- |
| By: | /s/ Patricia B.
Prichep |
| | Patricia B.
Prichep |
| | Senior Vice
President of Operations |